AI GLP-1 Companion is a health education agent that helps people considering or using incretin therapies navigate side effects, titration, nutrition, access, and long-term planning. Unlike generic chatbots that lose your dose day and GI pattern, this agent retains that history so guidance stays stage-specific. Built on Jenova's unified platform, it combines models from OpenAI, Anthropic, Google, and more with dose-day and coverage tools. This is educational support, not a diagnosis, prescription, or substitute for licensed medical care.
GLP-1 Companion explains how GLP-1 receptor agonists and dual GIP/GLP-1 agonists such as semaglutide and tirzepatide actually work — slowing gastric emptying, increasing satiety, and reducing food noise. The AI covers indications for type 2 diabetes, obesity, and related metabolic conditions, plus what is still emerging, without turning Ozempic, Wegovy, or Zepbound into a shopping list. Mechanism context is what makes later GI, muscle, and access advice fit the drug you are actually on.
GLP-1 Companion ties nausea, constipation, reflux, and fatigue to delayed gastric emptying so a previously normal meal is not treated as a willpower failure. Guidance focuses on eating patterns you can keep during week one and through titration, and it flags the under-eating trap that accelerates muscle loss, fatigue, and hair shedding.
GLP-1 Companion does not choose your dose, speed your titration, or tell you to hold a shot on its own authority. The AI explains typical weekly-injectable culture, missed-dose logic at a high level, and why staying at a dose another two to four weeks can be a reasonable question when nausea is still severe. Injection practicalities stay in the “what to ask your prescriber” lane, not DIY prescribing.
GLP-1 Companion puts protein-first meals and two to three weekly resistance sessions at the center of lifestyle support so more of the loss is fat rather than lean mass. Progressive overload is prioritized over extreme cardio, and meal structure is paired with training so you are not lifting in a severe calorie fog. Plateau troubleshooting stays honest: incretin therapy manages biology; habits help, but they rarely fully replace appetite signaling if you stop.
GLP-1 Companion walks through manufacturer savings programs, prior-authorization documentation, appeal logic, and patient-assistance pathways when brand-name GLP-1 medications run over $1,000 a month without coverage. Sourcing is ordered as a hierarchy: FDA-approved pharmacy channels first; compounding explained with quality, salt-form, and multi-dose vial risks; illegal online sales and “same as Ozempic” telehealth pitches treated as red flags — never as a catalog. Maintenance doses, molecule switches, and supervised stops are planned with regain in view, including that many people recover around two-thirds of lost weight within a year after cessation.
| Traditional Approach | GLP-1 Companion |
|---|---|
| Forum anecdotes and skipped meals | Stage-specific GI side-effect playbooks |
| Loses dose day between sessions | Remembers medication, symptoms, failed tactics |
| Cash pay or gray-market vials | Savings cards, appeals, approved channels |
| Sudden stop after denied refill | Maintenance, switch, or stop planning |
Unlimited Memory vs. Chatbot Amnesia
Generic chatbots forget that you inject on Thursdays, that high-fat lunches already triggered vomiting, and that you are mid-prior-authorization — then they recycle week-one tips into a month-four plateau or treat an approved pen as interchangeable with a compounded vial. GLP-1 Companion retains medication, dose day, GI pattern, protein struggles, and sourcing status across sessions. Continuity is what keeps Friday-at-work advice from undoing Tuesday’s plan.
Multi-Model AI Access
A same-day bland-food sequence after a Wegovy shot needs a different model posture than unpacking salt forms, 28-day vial discard rules, or prior-authorization language. ChatGPT locks you to OpenAI; Claude locks you to Anthropic. This agent can route across OpenAI, Anthropic, Google, xAI, DeepSeek, Qwen, and more inside one GLP-1 thread as the task shifts from GI coaching to an access briefing.
Intelligent Tool Integration for End-to-End Workflows
GLP-1 Companion is built to run a production loop, not a one-off chat: injection day and current symptoms go in; a bland lower-fat eating sequence, protein you can tolerate, and a red-flag check are processed; a same-day plan and prescriber questions come out. Calendar reminders, coverage searches, and saved prior-authorization notes keep that loop going between appointments. The workflow is stage and symptoms → plan and questions → documented next steps, not another forum thread.
Built for Incretin Therapy, Not Generic Diet Chat
General models can recite drug names. They do not reliably distinguish initiation from a plateau, or an approved Zepbound pen from a compounded multi-dose vial. This agent is organized around candidacy, titration culture, GI management, muscle preservation, insurance tactics, and discontinuation — and it will not prescribe a dose or send you to illegal sellers.
People in the first weeks of a weekly injectable
Nausea often peaks the day after the shot, and friends saying “push through” is not a plan. The AI turns delayed gastric emptying into a week-one eating pattern and a short update for your follow-up.
People facing coverage denials, impossible copays, or compounded-product ads
When Wegovy or Zepbound is medically appropriate but the plan says no, this agent walks legitimate cost-reduction paths and explains why a vial at a fraction of the price is often a quality and legal problem, not a bargain.
People who need a 90-second plan on injection day
Side effects show up at work, at dinner, and the morning after the pen — not during a scheduled hour at a desk. Open a chat, describe timing and symptoms, and get a same-day sequence instead of skipping food and overeating later.
People watching the scale drop while strength falls
Clothes fitting better is not the same as protecting lean mass. GLP-1 Companion treats protein distribution and two to three weekly resistance sessions as core treatment, not optional wellness.
People deciding whether to stay on, switch molecules, or stop
Long-term use, a lower maintenance dose, a switch, or a supervised stop are all valid if you know the regain tradeoffs. The companion helps you prepare that conversation before a denied refill forces a sudden halt.
Free For exploring Jenova:
Plus ($20/month) For individuals:
Premium ($50/month) For regular users:
Pro ($100/month) For power users:
Max ($200/month) For professionals:
Ultra ($500/month) For heavy professionals:
Enterprise ($1,000/month) For businesses:
All plans are billed monthly with no daily usage caps — your full quota is available immediately on each billing date.
GLP-1 Companion is an AI health partner for people considering or already using incretin medications such as semaglutide and tirzepatide. It turns mechanism, GI symptoms, muscle-loss risk, coverage denials, and stop-or-stay decisions into practical next steps and clearer questions for your prescriber. It is not a clinic, a pharmacy, or a prescription service.
GLP-1 Companion is organized around the incretin journey instead of generic weight-loss chat. It remembers your medication, dose day, GI pattern, and sourcing situation so it does not serve week-one nausea tips during a month-four plateau or treat an approved pen as interchangeable with a compounded vial. You can route across OpenAI, Anthropic, Google, xAI, DeepSeek, Qwen, and more when a same-day bland-food plan needs a different posture than compounding rules or appeal language. Calendar, search, and document tools then carry injection day, coverage briefings, and visit notes in one workflow rather than a single-vendor chatbot that only talks.
GLP-1 Companion can use Google Calendar for injection days and follow-ups, Google Search and Google Scholar for shifting coverage and compounding context, Google Drive or Notion for prior-authorization packets and protein notes, and Gmail for a short visit update you can send before an appointment. Those tools keep a stage-specific plan attached to the same thread as your medication history. The point is a continuous loop from symptoms to next steps, not a disconnected list of app names.
No. Dosing, titration speed, holds, and switches are medical decisions for the clinician who knows your history. The AI can explain typical frameworks, missed-dose logic at a high level, and questions worth asking — for example whether holding a dose another two to four weeks is reasonable if nausea is still severe. It will not prescribe, and it will not treat a calendar reminder as a dose increase.
Many people regain a large share of lost weight after stopping, often around two-thirds within a year, because appetite-regulating signals rebound and metabolic adaptation from weight loss remains. That is biology, not a character flaw. Options to discuss with your prescriber include long-term treatment, a maintenance dose, a planned taper, and a stronger protein and resistance-training floor — none of which should be chosen from sticker shock alone.
Yes. GLP-1 Companion works with full parity across web, iOS, and Android, which matters because nausea and under-eating show up at dinner, at work, and the morning after the shot. Settings and conversation history sync, so your medication, dose day, and what already failed stay in the same thread, and speech-to-text is available if you would rather talk through symptoms than type them. Download Jenova for iOS or Android.
No. This agent will not point you to illegal sellers, research-chemical listings, or gray-market vials. It explains a sourcing hierarchy that puts FDA-approved pharmacy channels first and describes real compounding problems: salt forms that are not the same active ingredient as approved semaglutide, multi-dose vials that should be discarded 28 days after first use, warm shipments, and telehealth red flags such as no clinician screening or “same as Ozempic” claims. Retatrutide and cagrilintide cannot be compounded under federal law.
GLP-1 Companion can walk you through manufacturer savings programs, prior-authorization documentation, formulary exceptions, appeal logic, and patient-assistance pathways when cash prices are unworkable. A Medicare demonstration has set a $50 monthly cost for certain GLP-1 medications for some Part D beneficiaries, but eligibility is not universal and commercial plans still vary widely. The AI drafts questions and documentation checklists; it does not file claims or guarantee coverage.
GLP-1 Companion treats protein-first meals and two to three weekly resistance sessions as part of treatment, not a later “wellness” add-on. Appetite suppression can slide into eating far too little, which speeds lean-mass loss, fatigue, and hair shedding even while the scale looks like success. If you feel weaker on stairs eight weeks in and have not lifted more than grocery bags, that is a signal to fix composition now, not after a plateau.
No. GLP-1 Companion provides educational health guidance, not a diagnosis, prescription, or substitute for licensed medical care. Dose changes, new medications, and red-flag symptoms belong with your clinician. Use the AI to stay oriented between appointments and to prepare clearer questions, not to replace a visit.
No. Conversations and data are not used to train public AI models, are encrypted in transit and at rest, and are not sold or shared with advertisers. That matters when you are logging GI symptoms, coverage denials, or medication names. Keep clinical decisions with your licensed care team.
Stop chatting and seek urgent or emergency care for severe abdominal pain, persistent vomiting, inability to keep down fluids, signs of an allergic reaction, or other red-flag symptoms your clinician has warned you about. GLP-1 Companion will not workshop a prompt through an emergency. Dehydration, mood changes, and vomiting that will not stop belong with a clinician, not a longer thread.
GLP-1 Companion is part of Jenova, the most powerful AI agent platform in the world. Jenova provides unified access to leading AI models from OpenAI, Anthropic, Google, xAI, DeepSeek, Qwen, and more — alongside intelligent tool integrations for end-to-end task completion. The platform features persistent cross-session memory, automated workflow orchestration, and full parity across web, iOS, and Android. Developed by Azeroth Inc., a New York-based technology company, Jenova serves users in over 70 countries.
For developers, the Jenova Agent API provides a fully-managed agent backend with built-in orchestration, multi-model routing, memory, storage, and MCP tool support — replacing the need to stitch together raw LLM APIs, vector databases, and custom tool servers.
Contact: [email protected]